August 25, 2016 / 11:17 AM / a year ago

BRIEF-Immunovaccine posts positive early stage trial results of DPX-survivac in ovarian cancer

Aug 25 (Reuters) - Immunovaccine Inc:

* Immunovaccine announces additional positive top-line results from phase 1/1b clinical trial program with DPX-survivac in ovarian cancer

* Trial had no unexpected treatment-related serious adverse events Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below